News

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

New phase 2b data shows the JAK1 inhibitor is beneficial for moderate to severe adult atopic dermatitis.

A new study from the Ohio State University found the commonly-prescribed blood cancer drug ibrutinib was linked to new or worsening hypertension, which investigators suggest could contribute to an increase in other cardiovascular events.

The Biovitals Analytics Engine is able to read physiology signals to allow doctors to change the trajectory of disease weeks in advance.

In a new meta-analyses, investigators find a lack of evidence showing the links between antidepressants and adverse health risks.

The largest improvements for patients taking ustekinumab occurred following treatment every 8 weeks.

How new agents, improved study outcomes, and priority on diagnosis has bettered the state of dermatologic care.

A study from investigators in Europe found the CCS, ACC/AHA, and NICE guidelines for statin use may be more effective at preventing ASCVD events than ESC/EAS or USPSTF guidelines.

Its approval was based on findings from the limited assessment of pediatric patients in PANORAMA-HF, showing reduction of a cardiovascular biomarker.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

A recent study of pregnancies from the Quebec Pregnancy Cohort found use of antidepressants during pregnancy was linked to an increased rate of gestational diabetes mellitus in an analysis that included more than 200,000 women from 1998 to 2015.

The challenge will bring together providers, institutions, patients, payers, and researchers from across the healthcare ecosystem with the goal of better understanding pain points in healthcare.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

From immunotherapy to biologics, the field of allergy pharmacotherapy is looking promising.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

How can physicians and specialists navigate testing options and potential risk factors to ensure patients are diagnosed and treated expediently and accurately?

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

There has been significant changes in understanding surrounding food allergy testing. What do parents need to know?

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

Investigators deem phase 2 study using pimavanserin to treat major depressive disorder a success.

The FDA approves Mavyret as an 8-week treatment for all genotypes of HCV with compensated cirrhosis.

The approval is based on findings showing patients on the drug plus VTd had a 53% reduction in risk of disease progression or death, compared to lone VTd.

In an extensive review of 18 cohort studies, investigators connect dietary patterns with chronic kidney disease incidence rates.

The Proclaim XR recharge-free system provides relieve through a low-dose proprietary BurstDR stimulation waveform, which mimics natural brainwave patterns that change pain signals traveling from the spinal cord to the brain.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.